ÂÜÀòÂÒÂ×

Ségolène Martin is the CEO and co-founder of Kantify, a TechBio company focused on accelerating drug discovery through Artificial Intelligence. Under Martin's leadership, Kantify has developed a breakthrough technology, Sapian, which demonstrates outstanding performance in target and small molecule discovery. Martin also serves as Vice-Chair and advisory board member at lifetech.brussels, and is a member of the Global Partnership on Artificial Intelligence's working group on Innovation and Commercialization. Additionally, involvement with the European Commission's Digital SME Focus Group on AI and as a former ambassador for Women in AI in Belgium highlights Martin's commitment to advancing AI and fostering inclusive networks. Prior experience includes roles at CEN and CENELEC, where Martin managed technical policy and innovation strategies, along with coordination of the Automotive Crisis Intergroup. Educational accomplishments include an MBA from The Open University and a master's degree in European Public Affairs from Sciences Po Strasbourg.